Tesamorelin
Stabilized GHRH Analogue — FDA-Studied
N-terminally trans-3-hexenoyl-modified GHRH(1-44) with enhanced plasma stability. Research focus on visceral-adipose reduction. Available in 10 mg and 20 mg sizes.
Growth Peptides
Category
From $107.99
Price
Research
Grade
Price
From $107.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Clinical protocol is 2mg subcutaneously once daily. Research protocols sometimes use reduced doses (0.5–1mg daily) to extend vial life at the cost of reducing proximity to the published-trial dataset. Evening dosing aligns with the endogenous GH pulse.
Tesamorelin is chemically full-length GHRH(1-44) with a single modification: a trans-3-hexenoic acid group covalently attached to the N-terminal tyrosine. That acylation blocks DPP-IV cleavage at the N-terminus, extending plasma half-life from roughly ten minutes (native GHRH) to around 26–38 minutes (tesamorelin), while preserving native GHRH-R binding and native pulse architecture.
Specifications
| Product | Tesamorelin |
|---|---|
| Category | Growth Peptides |
| Format | Lyophilized powder |
| Price | From $107.99 |
The N-Terminal Modification
Why a Single Hexenoyl Group Changes Pharmacokinetics
DPP-IV cleaves most GHRH analogs at the Tyr1-Ala2 bond within minutes. Tesamorelin's trans-3-hexenoic acid conjugation to Tyr1 sterically blocks that cleavage without affecting GHRH-R binding. Half-life triples, pulse architecture stays intact — a minimal-footprint engineering modification that is the entire pharmacokinetic story.
The VAT Endpoint
Why Tesamorelin Owns the Visceral Fat Literature
The Falutz 2007 NEJM trial and the Stanley 2014 JAMA follow-up established a reproducible ~17% VAT reduction signal specific to tesamorelin at 2mg daily for 26 weeks. No other GHRH analog has replicated that finding in a pivotal-trial setting, which is why research questions about visceral adipose respond to tesamorelin specifically.
The Research Positioning
When to Choose Tesamorelin Over Sermorelin
For pure GHRH-axis probing, sermorelin is the reference molecule. For body-composition research with visceral adipose as the endpoint, tesamorelin has the dataset. The compound selection follows the research question — not the other way around.
Reported Outcomes
Full-length GHRH(1-44) with trans-3-hexenoyl N-terminal acylation extending half-life to ~30 minutes
Only GHRH analog with FDA approval for a body-composition indication (visceral adipose reduction)
Pivotal trials (NEJM 2007, JAMA 2014) establish reproducible ~17% VAT reduction at clinical dose
Preserves native pulse architecture despite extended half-life
Specific comparator molecule for visceral-fat research questions
10mg vial sized for multi-day arms at clinical or reduced research cadences
Standard Protocol
Clinical protocol is 2mg subcutaneously once daily. Research protocols sometimes use reduced doses (0.5–1mg daily) to extend vial life at the cost of reducing proximity to the published-trial dataset. Evening dosing aligns with the endogenous GH pulse.
Pairs Well With
Ready to start?
From $107.99
✓ 10% off via PeptidesMuscle
Tesamorelin — FAQs
Other Growth Peptides Peptides
View All
CJC-1295 with DAC 10mg
CJC-1295 with DAC 10mg — the albumin-tethered GHRH analog that holds a steady-state GH elevation across roughly eight days from a single subcutaneous dose.
